181 results
8-K
EX-99.1
HZNP
Horizon Therapeutics Public Ltd Co
8 Aug 23
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
7:11am
as “Acquired in-process research and development and milestones” expenses in the condensed consolidated statement of comprehensive income. Amounts … recorded in this line item would have historically been recorded to research and development (“R&D”) expenses. The Company believes the new classification
8-K
EX-99.1
o9plh
3 May 23
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
7:06am
8-K
EX-2.1
8fq37nd4ltog
12 Dec 22
This Announcement Is Being Made Pursuant to Rule 2.7 of the Irish Takeover Rules
7:39am
8-K
EX-99.1
0p86js6obfveg8x5w
12 Dec 22
This Announcement Is Being Made Pursuant to Rule 2.7 of the Irish Takeover Rules
7:39am
DEFA14A
uo8608sz 1y
12 Dec 22
Additional proxy soliciting materials
6:31am
8-K
EX-99.1
znxxanbrlb
2 Nov 22
Results of Operations and Financial Condition
7:06am
8-K
e0dyb3i b77z
7 Oct 22
Results of Operations and Financial Condition
8:01am
8-K
EX-99.1
mtwqqoriyztidncqymc
3 Aug 22
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
7:06am
8-K
EX-99.1
knr9jk i61i
4 May 22
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
7:12am